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Abstract This work establishes the in vivo performance of
modiﬁed calcium phosphate bone cements for vertebro-
plasty of spinal fractures using a lapine model. A non-
modiﬁed calcium phosphate bone cement and collagen-
calcium phosphate bone cements composites with enhanced
mechanical properties, utilising either bovine collagen or
collagen from a marine sponge, were compared to a com-
mercial poly(methyl methacrylate) cement. Conical cement
samples (8 mm height × 4 mm base diameter) were press-ﬁt
into distal femoral condyle defects in New Zealand White
rabbits and assessed after 5 and 10 weeks. Bone apposition
and tartrate-resistant acid phosphatase activity around
cements were assessed. All implants were well tolerated,
but bone apposition was higher on calcium phosphate bone
cements than on poly(methyl methacrylate) cement. Incor-
poration of collagen showed no evidence of inﬂammatory
or immune reactions. Presence of positive tartrate-resistant
acid phosphatase staining within cracks formed in calcium
phosphate bone cements suggested active osteoclasts were
present within the implants and were actively remodelling
within the cements. Bone growth was also observed within
these cracks. These ﬁndings conﬁrm the biological advan-
tages of calcium phosphate bone cements over poly(methyl
methacrylate) and, coupled with previous work on
enhancement of mechanical properties through collagen
incorporation, suggest collagen-calcium phosphate bone
cement composite may offer an alternative to calcium
phosphate bone cements in applications where low setting
times and higher mechanical stability are important.
1 Introduction
Traumatic burst fractures of vertebral bodies accounts for
approximately 15% [1] of the estimated 19,000 annual
spine and neck fractures which result in emergency
admissions to hospital in England [2]. Such fractures are
typically treated conservatively with a combination of
analgesics, external bracing and bed rest; however, concerns
regarding the inadequacies of these treatments have led to
the increased indication of minimally invasive surgical
procedures for these fractures [3].
Percutaneous vertebroplasty (PV), an image guided
therapy involving the injection of bone cement into the
vertebral body, is one such treatment. One indication for its
use is osteoporotic compression fractures, where profound
and rapid pain relief, coupled with an increase in functional
activities, has been reported in up to 84 % of patients [4].
However, despite this, limited research has been conducted
into the use of PV in the treatment of more severe traumatic
burst fractures, consequently its routine application within
the clinical setting is yet to be realised.
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Currently, the cement of choice in PV is poly(methyl
methacrylate) (PMMA), which displays good biocompat-
ibility and haemocompatibility [5]. However, PMMA does
have some signiﬁcant drawbacks, including monomer
toxicity, high polymerisation temperatures and an increased
risk of fracture in adjacent vertebral bodies [6]. In addition,
it is a relatively bioinert material, whereas bioactivity can be
used to induce positive responses in vivo. This has led to the
investigation of calcium phosphate bone cements (CPCs)
for spinal and neck repair following burst fractures. CPCs
mimic the mineral phase of bone and are resorbable [7],
consequently promoting natural bone ingrowth and remo-
delling. As such they have the potential to be particularly
effective in the treatment of traumatic burst fractures which,
due to their typical mechanisms of injury, usually occur in
the younger population who, in general, have a greater
capacity for bone remodelling [8, 9]. However, despite this
promise, concerns regarding limitations in their mechanical
properties have limited the use of CPCs in the treatment of
burst fractures [10–12].
Incorporation of collagen into CPCs is one way to enhance
their mechanical properties. Approximately 95% of the
organic material in bone is type I collagen [13], which is
involved in both bone function and formation. Collagen has
been investigated as a biomaterial since the 1970s [14], both
directly, in the form of hydrogels, and as an additive to other
materials. Such work has shown that collagen, in part due to
its low antigenicity and biocompatibility [15], has the potential
to be highly beneﬁcial in the ﬁeld of bone regeneration.
It is hypothesised that, in addition to improving
mechanical properties, collagen incorporation will give rise
to biological beneﬁts. Increased in vitro cellular adhesion
has been observed as a result of bovine collagen incor-
poration into CPCs [16, 17]. Furthermore, an in vivo study
has demonstrated a bovine collagen-CPC composite to be
both biocompatible and resorbable [18].
Earlier work investigating both bovine collagen and
collagen extracted from the marine Demosponge Chon-
drosia reniformis (Nardo, 1847 [19]) has shown that
mechanical and handling properties of a novel CPC for-
mulated from 100 % α-tricalcium phosphate (α-TCP-CPC)
can meet several of the clinical requirements for PV through
collagen incorporation (Table 1) [20–23], without com-
promising in vitro biological performance [24]. C. reni-
formis has been identiﬁed worldwide, has a high collagen
content [25] and a low risk of detrimental toxic compounds
[26]. The fact that this species also reproduces asexually
suggests that harvesting of the sponge for collagen isolation
could be conducted on a commercial scale [27]. Swatschek
et al. [26] developed a method for isolating collagen from
C. reniformis and demonstrated its suitability as a substitute
for collagen from conventional sources. The collagen
exhibits many features associated with mammalian collagen
and, in some aspects, has been shown to display signiﬁcant
similarities to bovine collagen [28, 29]. Based on this and
the earlier investigations, the aim of this study was to assess
the in vivo biological response associated with collagen-α-
TCP-CPC composites, formulated using either bovine or
marine sponge collagens.
2 Materials and methods
2.1 Cement production
α-TCP-CPC was produced following a previously described
protocol [24] and shaped using polytetraﬂuoroethylene
(PTFE) moulds. Conical cement samples, 8 mm high with a
base diameter of 4 mm (Fig. 1), were produced for ease of
implantation and because such geometry has been sug-
gested for prediction of resorption by evaluating the short
term resorption proﬁles [30]. A conical sample also has the
advantage of more closely replicating the variable thickness
of cement that would result from injection into vertebral
cracks. Although such cements are injected minimally
invasively and set in situ clinically, using pre-formed
samples allowed precise control over sample geometry
which facilitated analysis and comparisons.
Similar methods, also described by Palmer et al. [24],
were used to produce the Collagen-CPC composites.
Brieﬂy, bovine derived collagen (Sigma-Aldrich, Gilling-
ham, UK) or collagen extracted from C. reniformis (Klini-
Pharm GmbH, Frankfurt, Germany) was incorporated into
α-TCP-CPC at a loading of 1 wt% to form composites
referred to as BC-CPC and MC-CPC respectively. Bovine
collagen ﬁbres were cryogenically ground using a Freezer
Mill 6850 (Rondol Technology Ltd., Stoke-on-Trent, UK)
for two cycles of 2 min, a method previously shown to
reduce ﬁbre length [31], prior to incorporation into the
powder phase. Marine collagen ﬁbres were suspended in the
liquid phase of the cement before mixing with the powder
phase.
Table 1 Mechanical and handling properties of CPCs (modiﬁed from
[21]) and typical values for PMMA bone cement (Colacryl B866,
Lucite International Ltd., UK) [53, 54] (mean ± standard deviation)
Property α-TCP-CPC BC-CPC MC-CPC PMMA
Compressive
strength (MPa)
31.6± 3.9 13.6± 2.3 37.8± 6.4 ~60
Compressive
modulus (MPa)
1145± 139 550± 51 1283± 211 >3000
Setting time
(min)
29± 1.1 25.2± 0.5 15.5± 0.5 ~15
Injectability (%) 52.6± 7.3 10.4± 1.5 55.9± 9.0 —
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A commercially available PMMA based cement routi-
nely used clinically for PV, Vertebroplastic® Radiopaque
Resinous Material (DePuy International Ltd., Leeds, UK)
(referred to herein as VP-PMMA), was used as a control.
VP-PMMA was prepared using the same PTFE moulds,
under aseptic conditions, as per the manufacturer’s
instructions. All of the CPCs were sterilised using gamma
(γ) irradiation in accordance with ISO 11137-1:2006 [32]
(Isotron Applied Sterilisation Technologies, Synergy Health
plc., Swindon, UK). This method of sterilisation has been
reported as the most suitable for collagen extracted from C.
reniformis [33].
2.2 Model selection
New Zealand White rabbits were chosen as the in vivo
lapine model (Thrush Hall Supplies, Co. Antrim, UK). All
rabbits were skeletally mature females of approximately
28 weeks old [34], with a weight of 3.59± 0.06 kg (Mean
± Standard Error). All procedures had ethical approval and
were conducted in accordance with the regulations deﬁned
in the UK Animals (Scientiﬁc Procedures) Act 1986.
2.3 Surgery
A total of 38 rabbits underwent surgery. Two rabbits
received implants unilaterally at the distal femoral condyle
of the right leg. The remainder of the rabbits received
bilateral implants. All defects were randomly assigned an
implant type: α-TCP-CPC, BC-CPC, MC-CPC, VP-
PMMA, or no implant, which was to conﬁrm that the
defects being used were critically sized. The rabbits were
divided into two groups to be sacriﬁced 5 weeks and
10 weeks post-implantation. These two groups consisted of
18 and 20 rabbits respectively. The 5 week group were
implanted with eight of each cement type and four empty
defects; the 10 week group were implanted with eight of
each cement type with six empty defects. These time points
were selected as they have previously been shown to be
appropriate for the assessment of new bone growth sur-
rounding, as well as resorption of, CPCs in a lapine model
[35].
The procedure was similar to that used by Clarke et al.
[36] and was conducted under aseptic conditions. Rabbits
were sedated and anaesthetised using a neuroleptanalgesic,
Hypnorm® (VetaPharma Ltd., Leeds, UK), administered
intramuscularly at 0.25 mL/kg and midazolam (HYPNO-
VEL®, Roche Products Ltd., Welwyn Garden City, UK),
which was administered intravenously at 0.5–1.5 mg/kg.
Both hind limbs were prepared for surgery by shaving,
draping and swabbing the surgical site with a chlorhexidine
based antimicrobial agent (ChloraPrep®, CareFusion UK
306 Ltd., Basingstoke, UK). An incision (~3cm) was made
medial to the patella, allowing lateral dislocation of the
patella. The femoral condyle was visualised and a defect
matching the size of the implant created by reaming with a
custom made hand-held steel drill. Prior to implantation the
defect was lavaged with a saline solution to remove any
bone debris, bone marrow and/or blood from the cavity. The
implant was then inserted into the defect so that the base of
the cone was ﬂush with the cortical bone before the patella
was reduced. The incision was closed in two layers; the
subcutaneous layer was sutured with an interrupted pattern
using absorbable sutures (Coated VICRYL™, Ethicon Inc.,
Livingston, UK); the same sutures were used to close the
skin using a continuous subcuticular pattern (Fig. 2).
Following the procedure the rabbits were given a broad
spectrum antibiotic (Baytril®, Bayer HealthCare AG,
Leverkusen, Germany) at 2 mL/kg subcutaneously and an
analgesic (Temgesic®, Reckitt and Coleman, Hull, UK)
subcutaneously at 0.5 mL/kg mixed 1:9 with saline solution.
Animals were monitored regularly postoperatively and
returned to single housing cages, were weight bearing
within approximately 2–3 h, and had access to food and
water ad libitum.
2.4 Sacriﬁce and sample collection
Animals were euthanised through the use of sodium pen-
tobarbital (Euthatal, Merial Animal Health Ltd., Woking,
UK), which was administered intravenously until perma-
nent cessation of circulation, generally ~0.7 mL/kg. The
implanted limbs were removed and cleaned of soft tissue.
Fig. 1 Conical cement sample (8 mm high with a base diameter of
4 mm) (color ﬁgure online)
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Femora were ﬁxed in 4 wt% paraformaldehyde in phosphate
buffered saline (PBS) (both Sigma-Aldrich, Gillingham,
UK) for two days at 4 °C then stored in 70 % ethanol, also
at 4 °C, until further examination.
2.5 Histological analysis
Following ﬁxation specimens were dehydrated through
graded alcohols followed by acetone (Sigma-Aldrich,
Gillingham, UK) before being embedded in a PMMA based
resin (Technovit® 9100 NEU, Heraeus Kulzer, Wehrheim,
Germany) according to the manufacturer’s instructions.
Embedded specimens were sectioned using an Accutom-50
precision cut-off machine (Struers Ltd., Rotherham, UK).
Sections of 300 µm were cut longitudinally through each
implant before being adhered to fully frosted microscope
slides (Fisherﬁnest, Fisher Scientiﬁc Ltd., Loughborough,
UK). Sections were then polished with an Alpha 2 Speed
Grinder/Polisher ﬁtted with a Vector™ Power Head (both
Buehler, Coventry, UK) prior to staining.
Sections were stained with a 0.25 % w/v Toluidine Blue
(TolBlue) solution (Sigma-Aldrich, Gillingham, UK) then
rinsed with water and allowed to air dry before viewing.
Enzyme histochemistry for tartrate-resistant acid phospha-
tase (TRAP), a commonly used technique for the detection
of osteoclasts, was also performed. Prior to staining, resin
was removed from the sections by soaking in acetone.
Sections were adhered to fresh slides and rehydrated
through graded alcohols to distilled water. The staining
solution was prepared from a kit (Acid Phosphatase, Leu-
kocyte, Sigma-Aldrich, Gillingham, UK) according to the
manufacturer’s instructions. Sections were incubated in the
reaction mixture at ambient temperature for 10–15 min until
red stained areas were visible. Sections were then covered
in an aqueous based permanent mounting medium (CC/
Mount™, Sigma-Aldrich, Gillingham, UK) and dried at
70 °C.
Fig. 2 Surgical procedure. a and b Incision created medial to the
patella. c and d Defect created by reaming with a hand-held drill. e, f
and g Implant press ﬁt into place until base of implant was ﬂush with
cortical bone. h Subcutaneous layer sutured with an interrupted pat-
tern. i Skin sutured with a continuous subcuticular pattern (color ﬁgure
online)
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TolBlue and TRAP stained sections were viewed under a
Nikon SMZ800 stereomicroscope (Nikon UK Ltd., King-
ston upon Thames, UK). Bone afﬁnity index (AI) was
calculated by measuring the percentage of the implant
perimeter that was in direct contact with bone [37] using
ImageJ (V. 1.46r, National Institutes of Health, USA).
Analysis of the TRAP stained sections was conducted using
Photoshop Elements 2.0 (Adobe Systems Europe Ltd.,
Maidenhead, UK). The implant and an area of surrounding
bone up to 1.5 mm distance from the implant in each
direction was selected and, within this selection, red pixels,
which were indicative of TRAP activity, were quantiﬁed.
2.6 Statistical analysis
One-way analysis of variance (ANOVA) was used to
identify signiﬁcant differences between cement formula-
tions. Where a signiﬁcant difference was indicated, pair-
wise comparisons to assess inter-group differences were
carried out using Tukey’s Honestly Signiﬁcant Difference
(HSD) tests provided the sample sizes were the same. If
sample sizes were not consistent pair-wise comparisons
were carried out using Gabriel’s procedure. All statistical
analyses herein were performed using PASW Statistics 18.0
(IBM Corporation, New York, USA). A probability value




Histological analysis of the empty defects conﬁrmed that
the defects created were critically sized with little evidence
of bone growth observed at either time point, excepting the
cortical bone which had “closed” the top of the defect
(Fig. 3a and b). At low magniﬁcations there appeared to be
similar bone apposition on each cement type. However,
under higher magniﬁcation, in general, bone growth was
occurring near the VP-PMMA implant but was not apposed
onto the surface (Fig. 3c). Conversely, bone apposition onto
the surfaces of the CPC implants was clearly visible
(Fig. 3d).
Some evidence of an inﬂammatory response in the form
of ﬁbrosis around the implant, was observed, but was not
conﬁned to a particular implant type or time point. How-
ever, a phenomenon was observed in several sections from
the VP-PMMA group at both 5 week and 10 week time
points where the implants appeared to be associated with
voids in the adjacent bone (Fig.3e and 3). 80 % of the
5 week sections showed such voids, decreasing to two-
thirds at 10 weeks. Generally, but not exclusively, these
voids were observed around the tips of the implants. Such
voids were not observed around the CPC implants or the
empty defects.
Although no voids were observed around the CPC
implants, these implants did display a different phenomenon
which was not present in the vast majority of VP-PMMA
group. The majority of the CPC implants at both time points
displayed differing degrees of crack formation within the
bulk material. The extent of cracking ranged from very
limited, to extensive cracking. A small number of implants
displayed cracks to such an extent that the implant was
broken into two fragments. In general, the majority of the
cracks formed at the widest region of the implant nearest the
outer cortical bone (Fig. 4a and b).
Where more extensive crack formation occurred some
instances of bone growth into these cracks was noted. This
generally occurred in cracks near the edge of the implant
(Fig. 4c), but was also observed deeper within implants
(Fig. 4d). In addition, TRAP activity was also observed in
the cracks (Fig. 4e and f).
3.1.2 Histomorphometry
In general, AI was higher for the CPC formulations when
compared with the VP-PMMA group. Following 5 weeks
implantation the mean AI was approximately 180% higher
in both collagen augmented CPCs than in the VP-PMMA
group; this increased to around 330 % in the α-TCP-CPC
group. Following 10 weeks implantation the mean AI
values for the α-TCP-CPC, BC-CPC and MC-CPC groups
were approximately 320, 410 and 470% higher, respec-
tively, than that of the VP-PMMA group. Despite this,
relatively large variations within groups resulted in few
statistically signiﬁcant differences. Following 5 weeks
implantation no signiﬁcant difference in AI was observed
between the three CPC formulations. Similarly, no sig-
niﬁcant difference in AI was observed when VP-PMMA
was compared against both BC-CPC and MC-CPC. How-
ever, α-TCP-CPC displayed a mean AI signiﬁcantly higher
than VP-PMMA (P= 0.01). Following 10 weeks implan-
tation there remained no signiﬁcant difference between the
AI values of the CPC formulations. However, both BC-CPC
and MC-CPC demonstrated AI values signiﬁcantly higher
than VP-PMMA (P= 0.007 and P= 0.01 respectively). In
addition, for each implant type, no signiﬁcant increase in AI
was observed between 5 and 10 weeks implantation
(Fig. 5).
TRAP activity was reduced between 5 and 10 weeks
(Fig. 6); however, as a result of the large variations, the only
statistically signiﬁcant decrease between time points was
observed in the BC-CPC group (P = 0.019). TRAP activity
in the MC-CPC, VP-PMMA and empty defect groups were
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similar with a trend towards higher activity in both α-TCP-
CPC and BC-CPC groups.
4 Discussion
The aim of this study was to assess the in vivo performance
of CPCs with enhanced mechanical properties through the
incorporation of collagen. In general, AI was higher for the
CPC based formulations than in the VP-PMMA group.
When the VP-PMMA implants were investigated bone
growth was observed in close proximity to the implant
(generally within 100 μm) but was rarely apposed onto the
implant. This ﬁnding is likely to be due to the good in vivo
osteoconductivity of CPCs [7, 38–42] coupled with the lack
of osteoconductivity associated with PMMA bone cement
[43]. These ﬁndings are in agreement with the work of Tsai
et al. [35], who noted excellent bonding between a CPC and
host bone in a rabbit model after 12 weeks implantation.
Similarly, in a study involving the injection of a CPC into a
canine model, the surface of the cement was almost entirely
covered with bone within 14 days of implantation [44].
The results suggest that incorporation of collagen may
initially slow bone apposition compared to the native
cement, but, by 10 weeks, apposition onto both collagen-
CPC composites matched that of the native CPC. This
ﬁnding is in line with the results of previous in vitro work
showing that cells were able to proliferate equally well on
all of the CPCs as well as differentiating on both α-TCP-
CPC and MC-CPC, albeit at shorter time points [24].
Few studies have assessed the incorporation of collagen
into CPCs. Mai et al. [18] incorporated bovine collagen into
Calcibon resulting in good bone integration, but the absence
of an non-augmented control meant that the effect of col-
lagen incorporation could not be quantiﬁed. In vitro ana-
lyses into the effect of collagen incorporation into CPCs
have generally focused on handling and mechanical prop-
erties [16, 17, 20, 45]. However, it has been shown that
incorporation of bovine collagen into CPCs can improve
cellular adhesion capacity [16, 17]. To the best of the
Fig. 3 a and b Empty defects at
the 5 and 10 week time points
respectively showing little
evidence of bone ingrowth. c
Bone growth close, but not
apposed, onto a VP-PMMA
implant following 5 weeks
implantation. Arrows indicate
space between implant and
bone. d Bone directly apposed
onto a CPC based implant (BC-
CPC) following 5 weeks
implantation. e and f Voids
observed around VP-PMMA
implants after both 5 and
10 weeks implantation,
respectively. Asterisks indicate
voids. Key: ED empty defect, B
bone, BM bone marrow and I
implant (color ﬁgure online)
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authors’ knowledge, this is ﬁrst in vivo study investigating
the incorporation of collagen from C. reniformis into a
CPC. As such the effect of this collagen on the in vivo
behaviour of MC-CPC is based solely on the experimental
results presented herein.
TRAP staining results suggest that the CPCs were not
being actively resorbed. This is not surprising given that the
CPCs set to form calcium deﬁcient hydroxyapatite
(CDHA), which resorbs very slowly [46]. However, unlike
PMMA, CDHA is eventually remodelled, a process that
may be accelerated given that PV results in thin tendrils of
cement injected into cracks within a vertebral body rather
than a bulk implant.
A general trend towards decreased TRAP activity over
time was observed. This may be a result of the waning of
initial trabecular bone repair. The trend towards a declining
osteoclast response over time suggests that active resorption
of the CPCs would indeed be a long-term remodelling
process. However, it must be considered that a relatively
consistent level of activity represents normal cellular func-
tion around an orthopaedic injury; a suggestion which is
reinforced by the TRAP activity observed round the empty
defects. Despite this, it should be noted that TRAP activity
is not conﬁned to osteoclasts [47, 48]; TRAP expression is
associated with the differentiation and activation of cells of
monohistiocytic phenotype which includes macrophages,
among others, in addition to osteoclasts. It is thus possible
that some of the TRAP activity observed may be as a result
of macrophages initiating the inﬂammatory response asso-
ciated with the injury. However, given that the ﬁrst time
point considered was 5 weeks, it is likely that any initial
inﬂammatory response would have subsided by this point.
Also, qualitatively, only limited signs of such a response
were observed when the sections from both time points in
this study were examined. Immunohistologic examination
of the sections would be required to conﬁrm or refute this
postulation.
In general, the CPCs investigated herein showed exten-
sive bone apposition, suggesting that these materials are
well accepted in vivo. Although no clear evidence of ﬁbrous
encapsulation was observed in the VP-PMMA group, the
differences observed in bone bonding between these
Fig. 4 a and b Cracking of
implanted CPCs after both 5 and
10 weeks implantation
respectively. c Bone growth in
cracks near implant edge. d
Bone growth deeper inside
implant. e and f Red stained
TRAP positive cells within
cracked CPCs after 5 and
10 weeks implantation
respectively. Key: B bone, BM
bone marrow, I implant (color
ﬁgure online)
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materials and the CPCs may be an indication that they were
not as well tolerated in vivo. In addition to the lack of bone
apposition onto VP-PMMA implants, this material appeared
to result in the formation of voids adjacent to the implants.
The cause of these voids remains unclear, but it is possible
that residual unreacted monomer was leaching out of the
implants and resulting in tissue necrosis. This is thought
unlikely as VP-PMMA implants were produced in advance
of the operative procedures, which would allow time for the
evaporation of any residual monomer which may have been
present; no histological evidence of necrosis was observed
either. The voids are also unlikely to be artefacts from
section preparation due their exclusive association with VP-
PMMA implants. Although the exact cause of such voids
has not been conﬁrmed, the lack of voids in the CPC
implants suggests that they are better tolerated in vivo than
the VP-PMMA implants.
The occurrence of cracks was far more prevalent in the
CPC implants, with only minimal cracks observed in the
VP-PMMA group; this was expected due to differences in
mechanical properties. Concerns have been raised regarding
the mechanical properties, particularly the fracture tough-
ness of CPCs, however, the non-augmented formulation
used herein has been shown to be within the clinical range
required for vertebroplasty [49]. Furthermore, incorporation
of both bovine collagen and collagen from C. reniformis has
been shown to improve the mechanical properties of this
CPC [20, 50]; although, in terms of the crack formation, no
clear differences were observed in this study. Given that the
CPCs investigated have demonstrated in vitro mechanical
properties within the clinical range required for PV, the
crack formation observed is not considered a concern.
Cracks forming within the implant may in fact be a positive
outcome by allowing cellular inﬁltration into the implant.
The majority of the cracks being located near the base of the
implant are likely a result of cortical bone growth around
the top of the implants, resulting in more stress on this part
of the implant. Where extensive cracking was observed,
some instances of TRAP staining and bone growth were
noted within the cracks. A loss of mechanical loading in
bone can be sensed by osteocytes, which play a key role in
bone remodelling [51, 52]. It is possible that the formation
of cracks within the implants resulted in perturbations in
mechanical loading in the apposed bone causing the onset
of remodelling, as osteocytes have been suggested to
determine which surfaces are resorbed by osteoclasts [52].
Movement of osteoclasts to such areas near the implant may
lead to subsequent migration into the cracks with many of
the cracked implants showing TRAP positive cells in these
regions. This would suggest that osteoclasts are present
within the cracks and are attempting to resorb areas of the
implant. Localised regions of bone growth, which were also
observed within the cracks, indicate that the osteoclast
activity is being followed by the deposition of new bone by
osteoblasts.
Fig. 5 Bone afﬁnity index (AI) of each cement type after 5 and
10 weeks implantation (mean ± standard error; α-TCP-CPC after 5 and
10 weeks, n= 6 and n= 7; BC-CPC after 5 and 10 weeks, n= 8 and n
= 7; MC-CPC after 5 and 10 weeks n= 6 for each; VP-PMMA after 5
and 10 weeks, n= 5 and n= 6). V denotes a signiﬁcant difference
between the labelled bar and VP-PMMA at the same time point; α
denotes a signiﬁcant difference between the labelled bar and α-TCP-
CPC at the same time point; B denotes a signiﬁcant difference between
the labelled bar and BC-CPC at the same time point; M denotes a
signiﬁcant difference between the labelled bar and MC-CPC at the
same time point
Fig. 6 Percentage of pixels TRAP stained within 1.5 mm of the
implant (mean± standard error; α-TCP-CPC after 5 and 10 weeks, n
= 6; BC-CPC after 5 and 10 weeks n= 7; MC-CPC after 5 and
10 weeks, n= 5 and n= 4; VP-PMMA after 5 and 10 weeks, n= 5;
Empty defect after 5 and 10 weeks, n= 3 and n= 5). α denotes a
signiﬁcant difference between the labelled bar and α-TCP-CPC at the
same time point; M denotes a signiﬁcant difference between the
labelled bar and MC-CPC at the same time point; * denotes a sig-
niﬁcant difference between time points within a sample group
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5 Conclusions
In general, all implant types were well tolerated in vivo with
little inﬂammatory response observed. However, the
majority of VP-PMMA implants at 5 week and 10 week
time points were associated with voids in the adjacent bone.
No such voids were associated with the CPC formulations
suggesting that they are better tolerated. Crack formation to
a varying degree was observed in the majority of implants,
though extensive cracks within the implant were mainly
conﬁned to the CPC formulations. This behaviour was not
considered to be a concern and may in fact prove beneﬁcial
by allowing cellular inﬁltration into the implant. Bone
apposition onto the implants conﬁrmed that the CPCs were
well tolerated in vivo and this was not compromised by the
incorporation of collagen from either source.
These ﬁndings, coupled with the knowledge that addition
of marine collagen signiﬁcantly improves the mechanical
properties of α-TCP-CPC, suggests that it may be a suitable
alternative to some of the most popular commercially
available bone cements in applications such as PV, where
mechanical stability is essential.
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